Abstract
Drug-induced lung injury (LIPL) is caused by the reaction of lung tissue to various drugs. One of the pharmacological groups capable of leading to drug damage to the lungs include monoclonal antibodies against T-lymphocyte receptors to enhance their cytotoxic function in order to treat unresectable or metastatic melanoma. As a result, the normal regulation of the immune system is disrupted, which can lead to immune-mediated side effects. One of the most dangerous complications of monoclonal antibody therapy is pneumonitis. Due to the variety of clinical and radiological manifestations of the disease described in the literature, it is necessary to consider LIPL as a diagnosis of exclusion, which requires the accumulation of data for effective diagnosis and management of patients. The purpose – to present for the first time a clinical case of lung damage in a patient with metastatic melanoma on the background of the use of a combination of Nurulimab and Prolgolimab. According to the clinical observation data of a 68-year-old woman, the importance of a detailed medical history collection for diagnosis has been demonstrated.
Keywords: drug-induced lung injury, nurulimab, prolgolimab, pneumonitis, metastatic melanoma.
For citation: Chernorotov V.A., Beloglazov V.A., Kuznetsov V.A., Kostenich V.S. Drug-induced interstitial lung injury in a patient with metastatic melanoma using a combination of nurulimab and prolgolimab. Clinical review for general practice. 2025; 6 (7): 13–18 (In Russ.). DOI: 10.47407/kr2025.6.7.00639
All accepted articles publish licensed under a Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.
